Anh Nguyen, MD, MBA
About Anh Nguyen, MD, MBA
Anh Nguyen, MD, MBA, is a Vice President and Therapeutic Sector Leader at Asklepios BioPharmaceutical, Inc., with extensive experience in medical affairs and drug development. He has held various leadership roles, including Medical Director at Xeris Pharmaceuticals and Health Policy Fellow at the United States Senate.
Current Role at Asklepios BioPharmaceutical
Anh Nguyen serves as the Vice President and Therapeutic Sector Leader at Asklepios BioPharmaceutical, Inc. (AskBio) since 2021. In this role, he oversees therapeutic development initiatives, focusing on advancing innovative treatments. His leadership contributes to the company's mission of developing gene therapies for various conditions.
Previous Experience at Xeris Pharmaceuticals
From 2017 to 2021, Anh Nguyen worked as the Medical Director at Xeris Pharmaceuticals, Inc. During his tenure, he was responsible for overseeing medical strategies and clinical development efforts. His role involved collaboration with cross-functional teams to ensure the successful advancement of therapeutic products.
Educational Background and Medical Training
Anh Nguyen completed his Doctor of Medicine (MD) at the University of Medicine and Dentistry of New Jersey. He furthered his medical training at Harvard Medical School, where he also engaged with Massachusetts General Hospital and Children’s Hospital Boston. Additionally, he earned a Master of Business Administration (MBA) with a focus on Finance from The University of Chicago Booth School of Business.
Board Memberships and Community Involvement
Currently, Anh Nguyen serves as a Board Member for Renaissance Social Services, Inc. since 2020 and for OutCare Health since 2022. His involvement in these organizations reflects his commitment to community health and social services, contributing to strategic decision-making and organizational governance.
Expertise in Clinical Development and Regulatory Affairs
Anh Nguyen has demonstrated expertise in various areas, including Regulatory Affairs, Global Clinical Development, and Medical Affairs. His experience encompasses drug development, particularly in gene therapy for pediatric rare diseases and oncology clinical trials. He has also engaged in pharmacovigilance and commercial launch strategies.